Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/29/21 | $40,000,000 | Series A |
Avalon Ventures Bregua Corporation Lilly Asia Ventures Myeloma Investment Fund Osage University Partners Prostate Cancer Foundation Vivo Capital | undisclosed |
